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Objectives: Bone marrow stromal cells are capable of differentiating into cardio-
myogenic cells. We tested the hypothesis that transcoronary implantation of bone
marrow stromal cells may regenerate infarcted myocardium and reduce cardiac
dysfunction.
Methods: Isolated bone marrow stromal cells from the isogenic donor rats were
transfected with LacZ reporter gene for cell labeling. To induce cardiomyogenic
differentiation, the bone marrow stromal cells were treated with 5-azacytidine
before implantation. Two weeks after left coronary ligation, these cells (1  106 in
150 L) were infused into the briefly distally occluded ascending aorta of the
recipient rats (n  15) to simulate direct coronary infusion clinically. Control
animals were infused with cell-free medium (n  14). Cardiac function was
evaluated by echocardiography at preimplantation and 4 and 8 weeks postimplan-
tation. The hearts were then immunohistochemically studied to identify phenotypic
changes of implanted bone marrow stromal cells.
Results: Immediately after cell infusion, the bone marrow stromal cells were trapped
within coronary vessels in both infarcted and noninfarcted areas. However, after 8
weeks, most of the cells were identified in the scar and periscar tissue, expressing
sarcomeric myosin heavy chain and cardiomyocyte-specific protein troponin I-C.
Some bone marrow stromal cells were found to be connected to the adjacent host
cardiomyocytes with gap junction. Two-way repeated-measures analysis of variance
revealed significant improvement in fractional shortening and end-diastolic and
end-systolic diameter of the left ventricle (P  .0465, .002, .0004, respectively) in
the bone marrow stromal cell group.
Conclusions: Although bone marrow stromal cells had been reported to improve
cardiac function when injected directly into the myocardial scar, this study demon-
strated for the first time that bone marrow stromal cells can be delivered via the
coronary artery, as they are capable of targeted migration and differentiation into
cardiomyocytes in the scar tissue to improve cardiac function.
With the recent advent in stem cell biology, it has been shownthat an adherent population of bone marrow cells in culturethat can be expanded in vitro, known as “marrow stromalcells” (MSCs), contain adult stem cells that can give rise tovarious mesenchymal and nonmesenchymal cell types.1-4Since Makino and colleague5 demonstrated that cardiomyo-
genic differentiation of MSCs in vitro in 1999, several in vivo studies including
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those of ours have confirmed this capability of the MSCs.6-9
The advantages of using MSCs as donor cells for cellular
cardiomyoplasty are that MSCs can be easily harvested
from patients’ own bone marrow by aspiration, can be
expanded vastly in culture to provide adequate numbers,
and can then be autoimplanted without encountering immu-
norejection. A clinical trial for the autologous transplanta-
tion of bone marrow cells into an unrevascularizable area of
the ischemic hearts to induce angiogenesis has already been
reported.10
Cells can be implanted into the myocardium in a number
of ways. To date, most of the experimental studies reported
have employed direct injection of various types of donor
cells into the myocardium.6,7,9,11-14 The advantage of this
procedure is that it enables one to transplant cells selectively
into specific areas of the myocardium. However, such an
approach is rather invasive and in particular not suitable for
patients with diffuse cardiomyopathy. In a recent study, we
confirmed the feasibility of delivering MSCs via the coro-
nary artery.8 As the MSCs were found to be capable of
migrating to an injured area after transplantation,15,16 we
hypothesized that MSCs, when infused into the coronary
artery, could engraft into an infarcted myocardium and
participate in myocardial regeneration and perhaps also
angiogenesis,10 resulting in an improved cardiac function.
In this study, we used a rodent model proximally injecting
MSCs into the briefly occluded ascending aorta, to simulate
clinical coronary delivery of these cells such as by selective
coronary artery catheterization, or by aortic root injection
during cardiopulmonary bypass.
Materials and Methods
Animals
Male inbred Lewis rats (200 to 250 g) were obtained from Charles
River Laboratory (Laprairie Co, Quebec, Canada). These isogenic
rats were used as donors and recipients to simulate the autologous
implantation of MSCs. All animals received humane care in com-
pliance with the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal Re-
sources, National Academy Press (revised 1996), and the “Guide
to the Care and Use of Experimental Animals” of the Canadian
Council on Animals Care.
Isolation and Cell Labeling
Isolation and primary culture of MSCs from the femoral and tibial
bone of donor rats were performed as previously described in
detail.7,8 A replication defective retrovirus containing the reporter
(LacZ) gene that encodes for the bacterial -galactosidase enzyme
were produced by LacZ-GPAM12 amphotropic retrovirus pro-
ducer cells originally obtained from Dr Jacques Galipeau’s Labo-
ratory (McGill University, Lady Davis Institute for Medical Re-
search, Montreal, Quebec, Canada).17 The second-passaged MSC
growth medium was replaced with the supernatant from the LacZ-
GPAM12 cells as described in detail before.8
MSC Treatment with 5-aza-2-deoxycytidine (5-
azacytidine)
MSCs that were harvested and labeled were treated for 24 hours
with 5-azacytidine [0.3 M solution in 10% Dulbecco’s modified
Eagle’s medium (DMEM)] within the culture dish. The cells were
incubated overnight in a 37°C incubator with a humidified atmo-
sphere of 5% CO2. The following day, the supernatant was re-
moved and replaced with 10% DMEM solution for 24 hours. The
cells were treated once more with 5-azacytidine for 24 hours and
the growth medium replaced. MSCs treated with 5-azacytidine
were infused into the coronary artery of recipient animals 24 hours
after the treatment.
Myocardial Infarction and Infusion of MSCs
Forty-one rats underwent ligation of the left coronary artery. Rats
were anesthetized with isoflurane (MTC Pharmaceuticals, Cam-
bridge, Ontario, Canada) and intubated and mechanically venti-
lated at 80 breaths/min. The heart was exposed via a left thora-
cotomy incision. The left coronary artery was ligated proximally
with a 6-0 polypropylene suture.8 Two weeks after the coronary
ligation, survived rats (n  29) were divided randomly into two
groups; rats infused with MSCs (MSC group: n  15) and rats
infused with culture medium (control group: n  14). Anesthesia
was induced and maintained with isoflurane. The ascending aorta
was exposed through upper median sternotomy and looped with a
suture after dissection. Under direct vision, transfected MSCs
suspension (1  106 cells in 150 L of DMEM) was then injected
into the root of the ascending aorta, while distally occluding the
aorta briefly for less than 3 seconds using the looped suture. A
28-G needle on an insulin syringe was used for the cell injection.8
Equivalent volume of serum-free culture medium was injected into
the control animals using the same procedure. Two animals from
the MSC group were sacrificed at 10 minutes after the injection to
observe initial cell distribution.
Echocardiography
Transthoracic echocardiography was performed on all animals at 2
weeks after coronary ligation before infusion of MSCs as baseline
and at 4 and 8 weeks after injection of MSCs or cell-free medium.
Echocardiographies were performed with a commercially avail-
able echocardiography system (SONO 5500, Hewlett-Packard)
equipped with 7.5-MHz transducer (Hewlett-Packard), and inter-
preted in a blinded fashion. Under anesthesia the heart was first
imaged in the 2-dimensional mode in the parasternal long-axis
view of the left ventricle (LV). Measurements of maximal LV
long-axis lengths (L) and endocardial area tracings (a), using the
leading edge method, were carried out.18 LV end-diastolic volume
(LVEDV) and LV end-systolic volume (LVESV) were calculated
by the single-plane area-length method19: V  8  a2/(3   
L). LV ejection fraction (EF) was then inferred: EF  [(LVEDV
 LVESV)/LVEDV]. M-mode images were obtained at the level
of papillary muscles of the mitral valves. End-diastolic and end-
systolic diameter of the LV (LVEDd and LVEDs) were deter-
mined. Fractional shortening (FS) was then calculated as [(LVEDd
 LVEDs)/LVEDd].
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MSCs Staining With X-gal for Detection of -
galactosidase Activity
Cells were plated in 35-mm dish. They were fixed in 1% glutar-
aldehyde for 5 minutes at room temperature, then washed with
phosphate buffered saline (PBS). Staining solution (500 L) at pH
of 8.0 was added, which contained 1 mg/mL 5-bromo-4-chloro-3-
indoyl--D-galactoside (X-gal), 1 mmol/L ethyleneglycol-bis-
(aminoethylether)-N,N,N,N-tetraacetic acid, 5 mmol/L
K3Fe(CN)6, 5 mmol/L K4Fe(CN)6.3H2O, 2 mmol/L magnesium
chloride, and 0.01% sodium deoxycholate.8 Then cells were incu-
bated at 37°C while protected from light for 16 hours.
Tissue Processing and Staining for -galactosidase
Activity
Animals were sacrificed at 1 day after the final echocardiogram (8
weeks after transplantation). As mentioned above, two animals in
the MSC group were sacrificed immediately after cell transplan-
tation to confirm the initial distribution of MSCs. Upon sacrifice of
animals, hearts were excised. The hearts were rinsed with PBS and
then perfusion fixed in 2% paraformaldehyde in PBS. The staining
for -galactosidase activity was performed as described above, but
with the addition of 0.02% of Nonidet P-40 and 0.01% of deoxy-
cholate to the staining solution.8 After X-gal staining at pH of 8.0,
the hearts were cut longitudinally and embedded in paraffin.
Histology and Immunohistochemistry
Heart sections 5 m in thickness were processed for H&E, Picro-
sirius Red, and immunohistochemical stains. Immunohistochemi-
cal stains were done for anti- smooth muscle actin (Sigma Lab-
oratories), endothelial cell marker factor VIII, and cardiomyocyte
specific troponin I-C (Santa-Cruz Biotechnology Inc). Stainings
were also carried out for sarcomeric myosin heavy-chain mole-
cules with MF 20 (Developmental Studies Hybridoma Bank de-
veloped under the auspices of the National Institute of Child
Health and Human Development and maintained by the University
of Iowa, Department of Biological Sciences) and connexin 43
(Zymed Laboratories Inc) as previously described.8 Briefly, after
deparaffinization, sections were placed in boiled citrate buffer (pH
6.0). After blocking in normal serum, sections were treated with
the respective monoclonal antibodies overnight and with second-
ary antibodies the following day. Diaminobenzidine (DAB) was
then used as a chromogen for light microscopy. Counterstaining of
sections with hematoxylin and eosin was also performed. Cells
derived from MSCs were identified by their blue nuclei (ie, -gal
labeled) with an Olympus microscopy (BX-FLA, Olympus).
Estimation of the Number of -gal-Positive Cells in
the Heart
We estimated the number of -gal-positive cells present in the
heart immediately after infusion by means of Weiss’ method,20
which had been validated for the rodent heart model when the cell
distribution could be assumed to be homogeneous. Briefly, cell
counts were made on 5-m-thick histological sections and surface
area of the myocardium on the section was measured by planim-
etry. Then cell number in certain tissue volume was referred to the
gross myocardium volume, which had been obtained by water
displacement technique.
Statistical Analysis
All data are expressed as mean  SEM. Repeated variables were
analyzed using a two-way repeated-measures analysis of variance.
Differences at each time point were compared by unpaired t test.
Statistical analysis was performed using a commercial software
(StatView version 5.0.1, SAS Institute Inc). A P value of .05 or
less was considered statistically significant.
Results
MSCs in Culture
The MSCs in culture were spindle-shaped, attached to the
bottom of culture dish tightly, and proliferated in the
culture medium. Approximately 3 to 4 passages after first
culturing the cells, they were expanded to over 25 million
cells from the initial 250 to 500 cells. To trace the fate of
MSCs after transplantation, we labeled MSCs with rep-
lication defective retrovirus carrying the LacZ reporter
gene, as described above. -gal staining in vitro demon-
strated that transfection efficiency was nearly 100%. Af-
ter treatment with 5-azacytidine, the cell cultures were
observed for morphological changes. However, we were
not able to find myotube formation or pulsating cells by
the time of implantation, as previously reported by
Makino and colleagues5 (Figure 1).
Mortality
Mortality within the first 2 weeks after coronary artery
ligation was 29.3% (12/41). Mortality within 8 weeks after
randomization and coronary infusions was 13.3% (2/15) in
the MSC group and 14% (2/14) in the control group.
Figure 1. -gal activity of MSCs. Histochemical staining for
-gal activity of rat MSCs in culture. The transfected MSCs
showed clear staining for -gal activity in their nuclei. Trans-
fection efficiency of the MSCs was approximately 100%. Original
magnification: 100.
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Histological and Immunological Assessment of
Engrafted MSCs
Immediately after infusion of MSCs, -gal-positive cells
were consistently found in all sections of the heart. They
were trapped within the coronary vasculatures in the non-
infarcted (Figure 2, A to C) as well as the infarcted areas
(Figure 2, D), mostly within capillaries and some in small
arterioles. No MSCs could be seen in the interstitium of the
scarred myocardium at this time. Approximately 3.45 105
MSCs, that is 34.5% of the cells injected into the ascending
aorta, were estimated to have been trapped within coronary
capillaries immediately after injection. Among them 73%
were seen in the noninfarcted myocardium of the hearts.
Most of the MSCs found in the myocardium were located in
the outer layer (subepicardial) rather than the inner layer of
the ventricular wall.
In contrast, nearly all of MSCs in the heart obtained at
8 weeks after cell infusion were seen within the infarct
zone and scattered diffusely (Figure 3, A and B). Immu-
nostaining for endothelial cell marker factor VIII showed
most of labeled cells were located outside of the vascular
lumens. These findings were consistent in all hearts of the
MSC group. The cells in the periscar area appeared
morphologically distinct from the cells in the middle of
the scar. MSCs in the periscar area were elongated and
had centrally located nuclei, with organized contractile
proteins such as sarcomeric myosin heavy chain and
cardiomyocyte-specific troponin I-C in their cytoplasm
(Figure 4, A and B). Picrosirius Red stain of the heart
section also revealed that those morphologically mature
MSC-derived cardiomyocytes were mostly located in the
subepicardial area of the periscar tissue (Figure 5, A and
Figure 2. Cell distribution in the myocardium. -gal positive cells were trapped in capillaries of both noninfarcted
(A and B) and infarcted myocardium (D). The hearts were harvested immediately after cell infusion. (A, B, and D)
Stained for H&E; (C) immunostained for endothelial cell marker, factor VIII. Arrows indicate -gal positive cells.
Arrowheads indicate epicardium of the heart. Original magnification: 40 (A), 200 (B and D), 400 (C).
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B). On the other hand, MSCs within the scar showed less
mature appearance despite positive stains for cardiac
specific proteins (Figure 4, C and D). They have a larger
nucleus-to-cytoplasm ratio and no recognizable striation
in their cytoplasm. Some MSC-derived cardiomyocytes
in the periscar area are seen to be connected to the
adjacent host cardiomyocytes with positive stain for con-
nexin 43 (Figure 4, E), a major constituent protein of gap
junctions in the intercalated disks of cardiac myofibers.
Some MSCs in the scar are integrated into vascular walls
and stained positively for -smooth muscle actin (Figure
4, F) or for endothelial cell marker, factor VIII.
In Vivo Cardiac Function
There was no statistically significant difference in EF (P 
.640), FS (P .858), LVEDd (P .122), and LVEDs (P
.176) at the baseline between the MSC and control groups
(Figure 6). However EF, which was obtained from long-axis
view of the LV, was significantly higher in the MSC group
compared with the control group following cell infusion (P
 .029 at 4 weeks, P  .026 at 8 weeks). Similarly, FS,
LVEDd, and LVEDs obtained from short-axis view of the
LV were significantly different between the groups at 8
weeks after cell infusion (FS, P  .025; LVEDd, P  .039;
LVEDs, P  .013). Time course changes between groups
after cell or culture medium injections are significantly
different in FS (P  .0465), LVEDd (P  .002), and
LVEDs (P  .0004). However, change in EF over time did
not reach statistical significance (P  .3575).
Discussion
In this study, we transplanted MSCs into the heart with
myocardial infarction by injecting cells into briefly distally
occluded ascending aorta. We previously reported that only
2% of cells delivered could be detected in the whole heart
harvested immediately after such an infusion.8 In the current
study, however, approximately 34% of cells were identified.
What we modified in cell infusion technique was to shorten
aortic occlusion period (from 30 seconds down to only 3
seconds), which can minimize bleeding and leakage of
donor cells from the needle-puncture site, and to give bolus
injection rather than a slower infusion. After bolus injection,
the cells were disseminated and trapped in vessels and
capillaries of not only the noninfarcted but also the infarcted
segment of myocardium. Although left coronary artery was
ligated proximally 2 weeks before cell infusion, heteroge-
neously formed, scarred myocardium contained patent ves-
sels even in the center of the scar, where MSCs could have
reached through the collaterals. Suzuki and coworkers21
have transplanted skeletal myoblasts via the coronary cir-
culation of temporarily arrested heart by cardioplegic solu-
tion using isolated perfusion apparatus, which was followed
by implantation of the heart to the abdomen of recipients. In
their study, engrafted cells were identified in all layers of the
heart. In our study; however, more cells were found in the
subepicardial zone of the myocardium rather than in the
subendocardium. This could be related to the lower systolic
intramyocardial pressure of the beating heart in the outer
layer of the myocardium. In contrast, at 8 weeks after cell
implantation, most of the cells were located in the infarcted
and peri-infarcted myocardium. Individual cells were seen
outside of the blood vessels and were scattered in and near
the scar. These findings were consistent with our previous
finding in which we reported the translocation of entrapped
cells from the coronary capillaries to the myocardial inter-
stitium.8
Figure 3. Cell migration to the infarct site in the heart. Harvested at 8 weeks after cell infusion, numerous -gal
positive cells were identified in the infracted myocardium (A and B). Arrow indicates epicardium. Original
magnification: 40 (A), 200 (B).
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Figure 4. Phenotypic changes of the MSCs. Immunostain for troponin I-C (A and C), MF20 (B and D), connexin 43
(E), and -smooth muscle cell actin (F). Note -gal positive cells in the peri-infarcted myocardium (A, B, and E)
were more elongated and mature compared to the cells in the midst of scar (C and D). In panel E, between -gal
positive cells (thick arrow) and -gal negative cells (host cardiomyocyte, thin arrow), there was a gap junction
positively stained for connexin 43 (arrowhead). (A–D, F) Arrows indicate -gal-positive cells. Original magnifi-
cation: 400 (A–F).
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Several in vitro and in vivo studies have confirmed the
plasticity of MSCs to differentiate into cardiomyocytes.5-9 It
has been suggested that to induce MSCs to differentiate into
cardiomyocytes, the cells need to be in close contact with
the myocardial microenvironment, but within a scar they
require in vitro treatment with 5-azacytidine prior to im-
Figure 5. Cardiomyogenic differentiation of the MSCs. Picrosirius Red staining to show connective tissue in red
and muscle in yellow. -gal positive cell (arrow) in the periscar showed blue nucleus in the yellowish cytoplasm.
Arrowhead indicates epicardium of the heart. Original magnifications: 100 (A), 400 (B).
Figure 6. Echocardiographic data. Echocardiogram was performed before coronary infusion as baseline (0 weeks),
4 and 8 weeks after coronary infusion. EF, Ejection fraction of left ventricle (A); FS, fractional shortening (B); LVEDd,
end-diastolic diameter of the left ventricle (C); LVEDs, end-systolic diameter of the left ventricle (D); dotted line,
control group (n  12); solid line, MSC group (n  11). *P < .05 by unpaired t test.
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plantation.6,7 Although the exact mechanism of action of
5-azacytidine has not been elucidated, Konieczny and col-
leagues22 proposed that embryonic cells contain a myogenic
determination locus in a methylated state while in a tran-
scriptionally inactive phase, which becomes demethylated
and transcriptionally active with 5-azacytidine, causing the
cells to differentiate into myogenic cells. Tomita and col-
leagues have reported that when implanted directly into a
scar, only MSCs treated with 5-azacytidine showed positive
staining for troponin I and myosin heavy chain, and they
contributed to improved cardiac function by preventing scar
thinning and chamber dilatation.6 The results of our more
recent study comparing 5-azacytidine treated with non-
treated MSCs appear consistent with their findings.23 In the
current study, we again confirmed the importance of the
microenvironment for cardiomyogenic differentiation. The
morphological appearance of the MSCs in the center of the
scar was different to those in the periscar area, where the
cells were surrounded by viable host cardiomyocytes. The
latter showed well-organized contractile proteins, with
small nuclei to cytoplasm ratio, and connected to adjacent
host cardiomyocytes with connexin 43 positive gap junc-
tion, although the cells within the scar seemed less differ-
entiated. We speculate that the cells found in the periscar
area might have received more adequate in situ signals for
cardiomyogenic differentiation than those within the scar.
Besides the cardiomyogenic phenotype, we also found some
labeled MSCs showing vascular endothelial or smooth mus-
cle cell phenotypes integrated into vascular walls. They
were likely involved in the angiogenesis and vasculogenesis
in the healing process of myocardial infarction.10
It has been shown that MSCs implantation results in an
improved cardiac function.6,9 Even though these studies
showed improvement in cardiac function, exact mechanism
remained unclear, as there was scanty evidence of gap
junction formation between neomyofibers in the scar and
the native myocardium outside of the infarct, making syn-
chronous contraction unlikely. It has been speculated that
function might be improved by the attenuation of adverse
remodeling and enhanced contractility of cardiomyocytes.
The improvement in regional function probably resulted
from a combination of factors including myogenesis and
angiogenesis.6 Clearly further mechanistic studies are war-
ranted.
Limitations in the scope of this study also prevented us
from addressing a number of important and relevant issues.
Recently there was a major concern about the existence of
true “pluripotent adult stem cells,” as Terada and cowork-
ers24 and Ying and colleagues25 reported that MSCs could
simply fuse with existing differentiated cells, with the ap-
pearance that they had differentiated into cells of other
phenotypes. However, this notion had been challenged sub-
sequently by a number of authors, such as that from Ver-
faillie’s group,26 who conclusively demonstrated that a sin-
gle adult stem cell derived from the bone marrow could be
guided to differentiate into various specific phenotype, in
the absence of any preexisting differentiated cell to which
an adult stem cell could fuse with. Tomita and colleagues27
cocultured MSCs with cardiomyocytes in vitro and reported
that the MSCs expressed various phenotype specific pro-
teins, such as troponin I-C, connexin-43, and atrial natri-
uretic factor, in sequence rather than simultaneously. This
observation also supports that MSCs undergo differentiation
rather than fusion. This is because in a fusion, the cardio-
myocyte that fuses with MSC should already contain all the
phenotype-specific proteins, so that it is not possible for
these markers to become detectable one by one over several
days. We have discussed the phenomenon of such milieu-
dependent differentiation in greater detail elsewhere.28
Another important limitation in this study is that we did
not attempt to use specific cell markers to characterize and
define the preimplant properties of MSCs, as we stated
earlier. It should be noted, however, that the clonal defini-
tion of MSCs is not fully standardized yet at present, as the
investigators still use various different cell markers, cellular
culture, and isolation techniques in their studies. Likewise,
the specific molecular signals for MSC homing and differ-
entiation remain unknown and will also need to be eluci-
dated in future studies.
Although intracoronary injection of cells provides cer-
tain advantages, coronary embolism leading to myocardial
infarction is a major concern with this delivery approach.21
In our preliminary study, we bolus injected a greater quan-
tity of cells (eg, 5  106) and found higher mortality rate
(more than 50%). As soon as the MSCs were infused, hearts
became pale and stopped beating due to embolism. There-
fore, to prevent embolic myocardial damage, measures to
avoid cellular aggregation, as well as slower or multiple
infusions of diluted cells, need to be considered. Clinically,
this approach may be most suited for patients who have
heart failure caused by diffuse cardiomyopathy.
We appreciate the technical assistance of Minh Duong, BSc.
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Discussion
Dr T. Rosengart (Evanston, Ill). I congratulate the authors on
a beautiful presentation. They certainly are pioneers in the field,
together with Dick Weisel and Philippe Menasche, and really have
led a growing body of evidence suggesting some very exciting
work in the possibility of cell transplant.
I have four questions for Dr. Saito. The first question involves
the use of 5-azacytidine to drive differentiation. Your histology
very elegantly shows apparent differentiation of cell lines based
upon the localization either to scar or periscar, appearing to go to
a myocyte differentiation or a fibroblast differentiation. Based
upon these findings, do you think that additional 5-azacytidine
would be efficacious or a more prolonged predifferentiation prior
to transplant?
In contrast, there certainly are a number of studies now sug-
gesting that undifferentiated cells, bone marrow or otherwise, may
equally be efficacious in driving myocardial remodeling. Given
concerns potentially by the US Food and Drug Administration or
other regulatory agencies in going to clinical trials in terms of
mutations, potential mutations, and complications using 5-azacy-
tidine, how do you see the role of using this or other differentiating
factors?
Dr Saito. We have not seen it.
Dr Rosengart. Do you think that the azacytidine plays an
important role, or do you think that simply transplanting undiffer-
entiated cells will be as efficacious?
Dr Saito. Yes, I think so. We have never seen myotube
formation or pulsating cells in a culture dish even after treatment
with 5-azacytidine. Possibly I don’t think 5-azacytidine worked.
Therefore, we reconfirmed the importance of a microenvironment.
Dr Rosengart. The second question involves the vascular
delivery, the arterial delivery, and certainly this has advantages in
terms of global dissemination, spreading of the cells throughout
the myocardium. The concern, of course, as you have shown in
your histology, is the risk of microembolization. Have you looked
at creatine kinase levels or other evidence of myocardial injury? Is
that a potential disadvantage of this delivery technique?
Dr Saito. Yes, it is a very important point. Actually we have
never checked the creatine kinase level, but if we infused more
number of cells, the mortality was much higher. For example, if I
infused 5 million cells as a preliminary study, more than half of the
animals died immediately after cell infusion. That was I think due
to microembolization. I have never seen a creatine kinase level.
Dr Rosengart. The third question involves your echo data, and
it appears very clear that when you look at your ejection fraction
and your end-diastolic and systolic volumes that you do have what
appears to be a stabilization of geometry or compliance. When you
look at your fractional shortening data at the 8-week time point,
you appear to have an improvement in function that is not consis-
tent with your other parameters. Do you have any explanation why
these parameters appear to be different?
Dr Saito. Ejection fraction was calculated using LVEDd and
LVEDs. That was presented. But when calculated, I also don’t
understand why only at 8 weeks marrow stromal cells show, how
to say, very improved cardiac function. But basically this value,
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